Futura Medical Share Discussion Threads

[lbo] 03/2/2023 13:33

Its just a placebo-nomics ‘form of fraud’ by rampers like Petroc. Arousal gels already on the market have the same alcohol, water, glycol and cabomer ingredients as Med3000!



Ingredients Water, ethanol (35%), propylene glycol, glycerin, carbomer, potassium hydroxide.

‘After a few moments there was a slight sensation of "cold and heat". Anyone who knows the more special lubricants’




A placebo is anything that seems to be a "real" medical treatment -- but isn't. It could be a pill, a shot, or some other type of "fake" treatment. What all placebos have in common is that they do not contain an active substance meant to affect health



A medical device has a ‘non-pharmacological, immunological or metabolic’ mechanism of action while a medicinal product has a ‘pharmacological, immunological or metabolic’ mode of action



‘Selling brass as gold harms consumers independent of any effect’

Since the placebo effect can be obtained from an arousal gel with the same ingredients) overcharging for a medical device gel that is represented as a miracle cure but works no better than a arousal gel ‘is a form of fraud’



Placebo-nomics: how bad was what Nurofen did?

Australian courts have ordered the makers of the brand to stop repackaging identical painkillers for different pains where does marketing end and deception begin?

Lies come in a wide range of ethical shapes and sizes. There are white ones, diplomatic ones, and there are mean, self-serving ones. Apparently there are even nice, Christmassy ones.

The Australian federal court yesterday ordered the drug giant Reckitt Benckiser to stop selling identical products marketed as specific Nurofen varieties for back pain, period pain, migraine pain and tension headaches. The company admitted the drugs sold in different coloured packets all contained the same active ingredient: 342mg of ibuprofen lysine. It also sold them at almost twice the price of Nurofen standard ibuprofen products.

Whether this constitutes deception or just marketing is probably one for the lawyers to argue over. Whatever its called, such practices might appear to fall pretty unequivocally towards the self-serving whopper end of the scale

[lbo] 03/2/2023 13:29

More like fitting adjectives for you trying to ramp an arousal gel! LOL

Ingredients Water, ethanol (35%), propylene glycol, glycerin, carbomer







water-based warming gel Ingredients

Stimulant Gel Aqua, Glycerin, Propylene Glycol, Alcohol Denat, Carbomer

[petroc] 03/2/2023 13:21

'Ironic how Petroc used the words ‘worthless and misleading’ '

Not ironic, LiarBO, just fitting adjectives for you and your stock bashing.

[lbo] 03/2/2023 12:39

Ironic how Petroc used the words ‘worthless and misleading’

How does he expect to get a patent for something that was clearly already described in research literature and contains all the same ingredients as arousal gels!



The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.


The brokers also admit in the recent research they are assuming the original Med2002/2005 patents which expire in 2025 in EU and USA in 2028 will provide some protection to Med3000 until then. Thats a big assumption as the original patent was an umbrella patent covering Dermasys with GTN. Med3000 is just Dermasys on its own and now just a medical device delivering only a cooling sensation via ‘evaporative cooling’



intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect.
The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial product


So no enforceable additional patent has still been granted. Its even questionable if that application protects Med3000 as its all about ‘methods of measuring the cooling abaility of a topical composition’. Presumably because GSK used a handheld device thermal device to measure the cooling of their alcohol and water gel so Futura have to make their patent look different! LOL

And Dermasys on its own has no patent anymore as Dermasys itself dates back to 2002.

[lbo] 03/2/2023 12:05

And still no update on an enforceable patent! I wonder why?https://futuramedical.com/media/2187/admission_doc.pdfThe royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offeredhttps://patents.google.com/patent/WO2021116651A1/enThe composition of the invention contained: ethanol: 33%; water: 35%; glycerol: 24%; propylene glycol: 6%; Carbopol® Ultrez 10: 1%. pH was adjusted to 5.25 with potassium hydroxide solution. The ethanol used in the manufacture of the composition was absolute ethanol (i.e. 100% ethanol free from water) such that the final composition contained 33% of pure ethanol. If a lower grade of ethanol was used which contained impurity amounts of water (e.g. 96% ethanol), then the amount used would have to be adjusted to ensure the final composition contained the correct amount of the components, i.e. 33% pure ethanol and 35% water.

[lbo] 03/2/2023 12:01

Arousal gel is a topically applied gel which utilises the same alcohol, water, glycol and carbomer ingredients as Med3000. Arousal gels too therefore have the same potential to be a highly differentiated product by addressing significant unmet needs in the ED market.



Ingredients

Water, ethanol (35%), propylene glycol, glycerin, carbomer









water-based warming gel

Ingredients Stimulant Gel Aqua, Glycerin, Propylene Glycol, Alcohol Denat, Carbomer



Even the market analysts know all Futura have done is paid for the research to allow competitors like Reckitt also claim all its class 2 medical device lubricants/arousal gels are also effective placebo treatments for Psychogenic ED!




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[lbo] 03/2/2023 10:02

Where is the long term and medium term safety data on the placebo Med3000 gel? It seems some MED impedance safety studies were just carried out in-vitro on cadavers!? Where are the studies on the long term consequences of not getting appropriate assessment for the real underlying cause of the ED and appropriately treating the real underlying cause rather then just using a placebo gel? A Viagra study also showed using a placebo was also just as likely to harm you. It compared some 4,500 patients taking the drug to about 3,100 on placebo. So based on that study Med3000 even as a placebo is just as likely to harm you as viagra




Concerns over regulation of oral powders or gels sold as medical devices in Europe



You are also forgoing all the other associated benefits of using oral PDE5I drugs like Viagra.



Patients taking the male impotence drug were found to have a lower risk of having a heart attack or dying from heart failure than those not on the medication.



Viagra could help men to live LONGER: Blue pill prolongs life and prevents heart attacks in males with coronary artery disease, study finds



Taking Viagra halves the risk of men who suffer from type 2 diabetes dying from heart problems



Taking Viagra could cut your risk of developing Alzheimer's by up to 69%



Viagra and other erectile dysfunction drugs may reduce risk of death from colon cancer by 20%

[lbo] 03/2/2023 09:56

Mike still at it I see! I ask myself does Mike only call Mr Barder a liar when he is asleep now! LOL

mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141

Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says

mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141

Company is massively over valued if you go by 'concrete' results !

mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141

I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !

mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591

"A couple of decent deals and will be back off to the races."
Do you have any idea of how long shareholders have been using these words

mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591

As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.
All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!

mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713

why should it be any different this time when you've still got the same useless lot running the show

mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641

I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life
And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration
I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

[lbo] 02/2/2023 21:33

https://www.washingtonpost.com/archive/lifestyle/wellness/2002/04/30/the-nocebo-effect-placebos-evil-twin/6945da76-fb8e-401e-a4f2-0439d36f4c6a/medical device gels like Med3000 'fall into this regulatory grey zone dont need to prove their efficacy or safety in the same way pharmaceuticals do, which could be a concern for vulnerable patients'https://www.massdevice.com/study-initially-ce-marked-medical-devices-higher-recall-rate/findings suggest that products introduced earlier in their development cycle are also more likely to increase the risk of harmshttps://www.chemistryworld.com/news/researchers-call-for-stricter-rules-on-drug-like-medical-devices/4011093.articleResearchers call for stricter rules on drug-like medical devicesMore oversight is needed over products in the grey area between medical device and medicationPowders, tablets and gels used like medications but registered as medical devices the same category plasters and pacemakers fall into need tighter controls, a team of clinical researchers has concluded after studying several such materials. Products that fall into this regulatory grey zone dont need to prove their efficacy or safety in the same way pharmaceuticals do, which could be a concern for vulnerable patientsAccording to European regulations, medical devices are used for diagnosis, prevention or treatment of disease, but unlike drugs their primary mode of action isnt biological. The definition includes everything from medical software to wound dressings and surgical instrumentsManufacturers need to demonstrate medical devices safety and performance. An organisation called a notified body then assesses the products conformity and grants it a CE mark. But Van Winckel and her colleagues found only poor clinical evidence for the three devices they investigated. Studies were small or of low quality, often missing placebo controls. In some cases, there was no data at all, for example to show the effectThe researchers also highlighted the lack of safety information in the devices instruction leaflets. There was no or little mention of interactions with other compounds, maximum safe dose or adverse effectshttps://www.bmj.com/company/newsroom/concerns-over-regulation-of-oral-powders-or-gels-sold-as-medical-devices-in-europe/Oral powders or gels, sold as medical devices in the European Union (EU), arent regulated to the same safety standards as those applied to medicinesAs a result, these products, which look like medicines, can be marketed with very limited clinical data and accompanied by poor quality product information.require only certification with a CE (quality) kitemark before the product can be marketed.This process doesnt require evidence of efficacy or safety from high quality clinical trials, as is the case for medicines.It also means that these products can automatically be sold without a prescription across the EU, and actively marketed to patients and clinicians.